BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Sanofi  Pharma  Bristol-Myers  Squibb  SNC,  France  submitted  to  the  EMEA  on 
26 November 1997 an application for marketing authorisation through the centralised procedure. This 
medicinal product was referred to Part B of the Annex of the Council Regulation EEC No 2309/93, 
indent 7 as it contains a new active substance. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Prof. F. de Andrés-Trelles 
Co-Rapporteur:  Dr. M. Toivonen 
Licensing status 
Irbesartan  150  mg/hydrochlorotiazide  12.5  mg  was  approved  by  the  US  Food  and  Drug 
Administration on 30 September 1997. Irbesartan 300 mg/hydrochlorotiazide 12.5 mg was submitted 
to the Food and Drug Administration for approval in December 1997. 
2.  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
An application for Marketing Authorisation was submitted to the EMEA on 26 November 1997. 
The centralised procedure started on 19 December 1997. 
The Rapporteur’s assessment report was circulated to all CPMP Members  on 18 March 1998. 
The Co-Rapporteur’s assessment report was circulated to all CPMP Members on 4 March 1998. 
The Rapporteur’s and Co-Rapporteur’s assessment reports and the comments from other CPMP 
Members were discussed during the CPMP meeting in April 1998 and the CPMP consolidated 
list of questions was adopted on 23 April 1998. 
The responses to the consolidated list of questions were provided on 11 May 1998. 
The joint Rapporteur’s and Co-Rapporteur’s assessment report on the responses provided by the 
applicant was sent to all CPMP Members on 3 July 1998. 
An  addendum  to  the  joint  Rapporteur  and  Co-Rapporteur  assessment  report  on  written 
clarifications provided by the company regarding quality issues was received on 14 July 1998. 
A hearing was held at the CPMP meeting on 22 July 1998, to address the remaining outstanding 
clinical issues. 
During the July 1998 CPMP meeting, in the light of the overall data submitted and the scientific 
discussion within the Committee, the CPMP issued a positive opinion for granting a Marketing 
Authorisation on 22 July 1998. 
The  European  Commission  issued  on  16  October  1998,  a  Marketing  Authorisation  valid 
throughout the European Union for the medicinal product Karvezide which contains irbesartan 
and hydrochlorothiazide. 
1/1 
   EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
